Table 2.
Clinical and pathological characteristics according to the MLR (n=118)
| Low MLR group (n = 45, %) | High MLR group (n = 73, %) | p value | |
|---|---|---|---|
| Age (years), median (range) | 61 (52-77) | 62 (42-83) | 0.932 |
| BMI (kg/m2), median (range) | 24.9 (16.7-31.6) | 24.7 (18.0-34.4) | 0.392 |
| FIGO stage | 0.001 | ||
| I | 33 (73.3) | 32 (43.8) | |
| II | 3 (6.7) | 3 (4.1) | |
| III | 7 (15.6) | 29 (39.7) | |
| IV | 2 (4.4) | 9 (12.4) | |
| Histology | 0.734 | ||
| Serous | 20 (44.4) | 37 (50.7) | |
| Clear | 11 (24.5) | 11 (15.1) | |
| Carcinosarcoma | 10 (22.2) | 20 (27.4) | |
| Un/Dedifferentiated | 4 (8.9) | 5 (6.8) | |
| LVSI | 0.004 | ||
| Absent | 33 (73.3) | 33 (45.2) | |
| Positive | 12 (26.7) | 40 (54.8) | |
| LN metastasis | 0.003 | ||
| Absent | 38 (84.4) | 43 (58.9) | |
| Positive | 7 (15.6) | 30 (41.1) | |
| Recurrence | 7 (15.6) | 44 (60.3) | < 0.0001 |
| Death | 6 (13.3) | 34 (46.6) | 0.003 |
MLR, monocyte-to-lymphocyte ratio; BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; LN, lymph node.